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Abstract
Background: Current evidence indicates sub-optimal incidence of fertility preservation (FP) in eligible patients. We
present herein our designated multidisciplinary program for FP in pediatric and adolescent population and present
our data on FP in female patients.
Methods: Pediatric patients (age 0–18) who were candidate for highly gonadotoxic treatments were referred to FP
program for a multidisciplinary discussion and gonadal risk-assessment followed by either oocyte cryopreservation
or ovarian cryopreservation (OCP) for female patients, and sperm banking for male patients. The OCP protocol
consists of aspiration of oocytes from small antral follicles and in-vitro maturation followed by cryopreservation, as
well as ovarian tissue cryopreservation.
Results: The establishment of a designated FP program resulted in a significant increase in referral and subsequent
FP procedures of all eligible patients. Sixty-two female patients were referred for FP discussion during a period of
36 months; 41 underwent OCP; 11 underwent oocyte cryopreservation and six were declined due to parental
decision. The median age was 13.2y (range 18 months-18y). Thirty-two (51.6 %) were chemotherapy-naïve.
Seventeen patients (27 %) had sarcoma, 16 patients (26 %) had acute leukemia. The mean number of mature
oocytes that were eventually vitrified was significantly higher in chemotherapy-naïve patients compared with
chemotherapy-exposed patients (mean 12 oocytes (1–42) versus 2 (0–7)).
Conclusion: Multidisciplinary programs that encompass experts of all relevant fields, skilled laboratory resources
and a facilitated path appear to maximize the yield. We observed a considerable higher referral rates following
launching a designated program and earlier OCP in chemo-naïve patients that culminated in a better fertility
preservation procedure.
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Background
Approximately 12,000 adolescents and children under the
age of 18 are diagnosed with cancer each year in the United
States. Fortunately, therapeutic advances have resulted in
increased survival while five-year survival rate for pediatric
cancer currently approaches 80 % [1, 2]. Cancer during
childhood and adolescence introduces major challenges re-
garding treatment-related late effects, and as survival rate
improves, there is much attention on interventions to im-
prove the quality of life during survivorship [2].
Up until 2013, the standard methods to preserve fertil-
ity were ovarian transposition for female patients under-
going pelvic radiation and embryo cryopreservation for
pubertal female patients before initiation of gonadotoxic
chemotherapy, whereas oocyte preservation and ovarian
cryopreservation have been considered experimental. Re-
cently, the American Society for Reproductive Medicine
(ASRM) revised its guidelines for fertility preservation
(FP) in cancer patients and acknowledged oocyte har-
vesting and cryopreservation as an ancillary standard
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procedure of FP prior to gonadotoxic treatment. Follow-
ing the establishment of ASRM that pregnancy rates re-
semble in both oocyte cryopreservation and embryo
cryopreservation; the American Society of Clinical On-
cology (ASCO) has concurred its recent guidelines with
those of the ASRM, stating oocyte cryopreservation is
recommended as a standard option for FP for pubertal
females [3]. This revision carries highest impact for
young pubertal female patients that until recently were
asked to preserve embryos using donor sperm, with
complicated future implications who now may undergo
a much useful methodology that may better serve their
future needs whether facing late-term infertility. For pre-
pubertal girls, ovarian tissue cryopreservation is the only
option to restore gametes. Since the benefit to the pa-
tient is not yet established, ASCO and ASRM guidelines
state that ovarian tissue cryopreservation should be
considered experimental and offered only in a research
setting with Institutional Review Board (IRB) approval
[3]. Ovarian cryopreservation has been widely studied
and methods have improved in many cancer centers
worldwide [4–6].
Fertility preservation in pediatric and adolescent pa-
tients has gained better appreciation throughout the past
years with improving rates of ovarian cryopreservation
and continuous crosstalk and collaborative frameworks
between oncologists and reproductive endocrinologists
and with the advent of skilled laboratories that handle
ovarian tissue [3, 4, 6].
This unique population presents psychosocial chal-
lenges derived from the decisions about FP, which may
have a substantial impact on the adolescent as an adult
survivor. For the pediatric patient, these bothersome de-
cisions are taken by her caregiver, what may aggravate
the primary stressful situation [7].
Former studies indicate that adolescents with cancer
appreciate information prior to initiation of treatment
on gonadal toxicity and potential impact to future fer-
tility, valid options for FP and wish to take active part
in the decision making process regarding FP [7]. Sev-
eral studies confirm that adult survivors of pediatric
cancer regret they had not been given more detailed in-
formation of options about FP, even though experimen-
tal [8–10]. For parents feeling uncertain in making the
decision about FP on behalf of their young girl, the
ASRM [8] offers guidance for counseling parents of
children with cancer of either sperm banking or ovarian
cryopreservation. Several studies have implied that es-
tablishing the right setting for fertility counseling for
young patients and parents regarding fertility and can-
cer treatments carries high implications to alleviate the
psychological stressors associated with both the ac-
knowledgement of cancer diagnosis and the risk of fu-
ture infertility [9–11].
Fertility represents a key issue in cancer survivorship
of pediatric or young adult patients. Follow-up surveys
developed by ASCO aiming at cancer survivors indi-
cate that those who are infertile following anti-cancer
treatments are at increased risk for emotional distress
[12–14]. Yet, despite the paramount significance, the
current evidence points at a sub-optimal approach to
discussion of FP by the health care providers reflected
by still lower referral numbers of eligible patients to
FP or even routine discussion on this matter. The lit-
erature implies that although most oncologists recognize
the importance of raising the issue of treatment-related in-
fertility, the actual lack of discussion may derive from de-
sire to commence immediate treatment and sub optimal
connection between oncologists and reproductive endo-
crinologists [11–13].
On this ground we have developed a unique program
that aimed at facilitating the daily practice and collabor-
ation between the various contributors to the process of
fertility preservation, emphasizing practical issues of en-
hancing the end-products of the process, focusing on
the psychosocial aspects and utilizing this platform to
prospectively assess gonadotoxicity throughout time fol-
lowing anti-cancer treatments under IRB approval. The
program serves male patients (for sperm banking and re-
cently a newly approved protocol of testicular biopsy
cryopreservation) and female patients (oocyte and ovar-
ian cryopreservation). The availability of providing bank-
ing of gonadal tissue requires a unified multidisciplinary
team with appropriate laboratory resources. We herein
present our paradigm, the shift in referral of pediatric
and adolescent patients in the last 36 months following
launching the program and our experience of fertility




Pediatric patients (0 – 18 years) from three cancer centers
(Schneider Children’s Medical Center/Rabin Medical Cen-
ter (SCMC/RMC), Ruth Rappaport Children's Hospital,
Rambam Health Care Campus, Haifa and Ha’emeck Med-
ical Center in Afula, Israel) who were candidates for highly
or intermediate-high gonadotoxic treatment (i.e., alkylat-
ing agent-based, induction chemotherapy for bone mar-
row transplantation (BMT), pelvic/abdomen radiation or
high-dose platinum based protocol) were referred to the
program. Following a referral algorithm (see below), and
in the presence of psychosocial counselor, the parents
(and also the patient, in case of adolescents (>12 years))
signed the informed consent for FP procedure as well as
an informed consent for the longitudinal follow up on
gonadotoxicity (the protocol was approved by the institu-
tional review board of Rabin Medical Center/Schneider
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Children’s Medical Center, to which all patients were re-
ferred; RMC −11-6549). Prepubertal girls were referred
for ovarian tissue cryopreservation while pubertal girls
were referred for oocyte cryopreservation if possible ac-
cording to time constraints defined by her oncologist and
time during menstrual cycle/first day of menstruation. In
case of highly gonadotoxic regimen administered to pu-
bertal girls that have not been exposed recently to chemo-
therapy, the goal was to have both ovulation induction
and oocyte cryopreservation and afterwards ovarian tissue
cryopreservation due to the very high probability for go-
nadal failure after treatment.
On the first appointment a questionnaire containing
demographic and medical obstetrical information is be-
ing collected. Before fertility preservation – either ovula-
tion induction or ovarian retrieval, blood is drawn for
hormonal profile (Follicle Stimulating Hormone (FSH),
Luteinizing Hormone (LH), Estradiol) and Anti Muller-
ian Hormone (AMH). In case of ovarian cryopreserva-
tion, a second tube of blood is drawn after surgery to set
a baseline value with less ovarian tissue and before the
initiation of chemotherapy. Serum is being drawn every
6 months in the first year and annually from the second
year for the same factors.
Fertility preservation options in pediatric and adolescent
female patients
Figure 1 illustrates the options for fertility preservation
in young female patients. For prepubertal patients ovar-
ian tissue cryopreservation is considered the only valid
option, yet it is considered experimental and requires
IRB approval. This procedure entails removal of tissue
from part or all of an ovary (by the discretion of the
surgeon upon the size of the ovary; in very young girls
usually a whole ovary is excised) which is then cryopre-
served for future use. The future use of the tissue car-
ries two alternatives: reimplanting an ovarian section or
the entire ovary into the patient. Several dozens of live
births were documented using this technology, yet only
in adult patients at the time of ovarian cryopreserva-
tion. Ovarian cryopreservation in younger children has
been frequently reported, nevertheless, there have been no
reports of live births after performing this procedure dur-
ing prepuberty mainly due to the young age of the treated
patients and the relatively short time that had passed since
ovarian cryopreservation [15, 16]. National Comprehen-
sive Cancer Network (NCCN) guidelines consider ovarian
cryopreservation is an investigational method of FP since
the possibility of reseeding cancer cells through reim-
planted tissue is still valid [17]. The second use of ovarian
tissue is in vitro maturation of primordial follicles. The
ovary, especially of young girls is enriched with copious
number of primordial follicles that may potentially serve
as “oocytes bank” for use. The process of in vitro follicular
maturation is being extensively investigated, yet complete
maturation of primordial follicles has not yet been
achieved yet in human. Results in animal studies are
promising due to major advances in recent years [18].
In 2013, ASCO has recognized oocyte harvesting and
cryopreservation as a standard option of FP [3]. The full
ovulation induction starts at the beginning of menstrual
cycle and hence ranges in the required time depending
upon the last menses of pubertal patients. In vitro mat-
uration (IVM) of pre-antral follicles enables maturing of
immature (growing) follicles in the laboratory and vitrifi-
cation of mature oocytes. Yet, IVM is not feasible after
Fig. 1 FP options for prepubertal girls and pubertal adolescents. a Current evidence for ovarian cryopreservation. b Schematic representation of
in vitro oocyte maturation (IVM) and subsequent cryopreservation. c Ovulation induction and oocyte retrieval and cryopreservation
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natural ovulation has occurred, but serve as an axillary
option when time constraints do not allow full ovulation
induction, while the patient is in the proliferating phase
of the menstrual cycle (before ovulation).
Referral algorithm
Since the establishment of the program, we had refined
our multidisciplinary approach upon the patient/parents’
feedback. The program comprised of two parts – the
adult program, for young adult female and male patients
treated at Davidoff Center, and the pediatric part which
during the time had expanded to referral from 3
pediatric cancer centers. The moderator is an oncologist
with prior academic background in reproductive biology
that is committed to this program and receives a notifi-
cation from the pediatric oncologist regarding a new pa-
tient, the diagnosis, treatment plan and timing (Fig. 2).
The first appointment occurs at the cancer center with a
detailed discussion, using educational tools about the
impact of the treatments on fertility and description of
FP options. Usually, the parents are very distressed
throughout this session and worry also about the impact
of FP on cancer treatment. After this discussion if the
parents/adolescent patients express their wish to con-
tinue with FP they are referred to a second professional
discussion in the reproductive endocrinology facility, by
a team consisting of the oncologist (moderator), a repro-
ductive specialist and psychologist who is an integral
part of the reproductive endocrinology unit. During this
meeting the parents are also asked to sign the informed
consent. After this appointment the patient continues
for a preoperative assessment. For ovulation induction
in pubertal girls there is a continuous consultation with
the pediatric oncologist to fit time constraints. In case
the patient needs to commence treatment very soon, if
she is in the follicular menstrual cycle phase (before
ovulation), oocyte aspiration and an in vitro maturation
procedure may be performed. Pubertal male patients are
referred to sperm banking following the multidisciplin-
ary discussion, and recently we had launched a protocol
of testicular biopsy for prepubertal boys and adolescents
in whom sperm banking is not feasible.
Surgical considerations
All patients underwent laparoscopic harvesting of ovar-
ian tissue under general anesthesia using one 10-mm
port positioned at the umbilicus and two 5-mm ports,
one at the left lower quadrant and one at the right. Par-
tial or complete, unilateral oophorectomy was performed
according to the consensus decision of the pediatric on-
cologist, the surgeon, and the medical staff of the IVF
unit, based on ovarian size and the anticancer treatment
protocol. The average OR time was 40 min and dissection
was carried out avoiding use of any device that may in-
duce collateral electric or thermal injury to the ovarian tis-
sue. Adolescent females with a larger volume of ovarian
tissue underwent partial ovariectomy, while pre-pubertal
girls with small ovaries underwent complete ovariectomy,
according surgeon’s discretion. Ovarian evacuation re-
quired an endo-bag, fresh tissue was sampled for patho-
logical examination and the bulk of ovarian tissue was
forwarded to the laboratory in a maximum 30 min. No
Fig. 2 referral algorithm Oncofertility program at RMC. Team is comprised by REI, Oncologist (moderator), Psychologist. The lower part represents
the components of the prospective study for longitudinal evaluation of reproductive outcomes in this cohort
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complications were recorded. All patients had a benign
postoperative course and were discharged the next day. In
follow up, no wound infection or port-side hernias were
detected and cosmetic results were excellent. Our prelim-
inary experience with laparoscopic technique was already
published [19, 20]
Ovarian cryopreservation
Prior to ovarian cortex slicing, germinal vesicle (GV)-
stage oocyte are being aspirated from small antral folli-
cles (>2 mm) in the operating room or/and manually
from the ovarian tissue [21]. Isolated oocytes are incu-
bated in IVM medium for 24 h and all intact oocytes
matured 24–48 h post retrieval are being vitrified. Ovar-
ian slices containing primordial follicles are being frozen
as well (slow freezing).
Assessment of referral trends among pediatric
oncologists
Female patient database of SCMC was screened and data
extracted of all female patients treated with highly gona-
dotoxic regimens (defined as: high dose alkylating agents,
bone marrow transplantation, total body irradiation (TBI))
from 2009–2011 (prior to the establishment of the pro-
gram) and between 2012–2014 (following launching the
program). Referral rates to fertility preservation were
assessed by disease for the two corresponding timeframes.
Patient data was reviewed for disease type, patient age and
prior exposure to chemotherapy.
Results
Cohort demographics
The program at Rabin Medical Center/Schneider Chil-
dren’s Medical Center (same campus) was launched at
1/2012. Prior to the establishment of the program, fertil-
ity preservation in pediatric population had been per-
formed in our center, yet not as a designated program
but rather on a case to case basis. In 36 months of its ac-
tivity 62 pediatric patients had been referred from
Schneider Children’s Medical Center, Ruth Rappaport
Children's Hospital Rambam Health Care Campus, Haifa
and Haemeck Medical Center in Afula, Israel, all were re-
ferred to the RMC/SCMC program. The median age was
13.2 (range 18 months–18 years). Thirty two (51.6 %)
were chemotherapy-naïve. Sixteen patients (26 %) had
acute leukemia (ALL and AML), before bone marrow
transplantation. Twelve patients were candidates for ovu-
lation induction and oocyte cryopreservation (pubertal pa-
tient with regular menses, intermediate-risk protocol and
chemotherapy delay was approved by the oncologist). Fifty
patients were candidates for ovarian cryopreservation. Of
All patients that were referred to FP discussion (n = 62),
41 patients underwent ovarian cryopreservation; 11
underwent oocyte cryopreservation. Six patients withdrew
the procedures for parental reasons, and in four cases the
planned treatment protocol had been changed to less
gonadotoxic protocol and hence FP was declined. Charac-
teristics of referred patients are demonstrated in Fig. 3.
Reproductive outcomes
Prior to ovarian cortex slicing of the excised tissue
exported from the operating room (as described in the
method section), germinal vesicle (GV)-stage oocyte were
aspirated from small antral follicles (>2 mm) manually
from the ovarian tissue. Isolated oocytes were incubated in
in vitro maturation (IVM) medium for 24 h and all intact
oocytes that matured 24–48 h post retrieval were vitrified.
Ovarian slices containing primordial follicles were frozen
as well. As presented in Fig. 4, the mean number of ma-
ture oocytes that were eventually vitrified was doubled in
chemotherapy-naïve patients compared with patients that
had previously been treated with chemotherapy (within
the last 6 months). For many of the previously-treated pa-
tients, no small antral follicles were observed, reflecting
the high vulnerability of this follicle population to chemo-
therapy, even those which is considered low gonadotoxic.
Shifting paradigms – referral rate before and after the
establishment of the program
Schneider Children’s Medical Center of Israel is a ter-
tiary referral center and is considered the largest in
Israel. Patient database at SCMC was searched for all fe-
male patients eligible for fertility preservation (candidate
for highly gonadotoxic regimens) by cancer type and age
between 2009–2014. Figure 5 describes the significant
change in referral rate in chemotherapy-naïve patient
population. Among patients with bone cancer (osteosar-
coma and Ewing sarcoma) referral rate increased from
27.3 % to 73.7 % after the establishment of the program
(3/11 patients and 11/15 patients respectively). This
group also represents mainly post pubertal patients con-
sidered for oocyte cryopreservation. Among patients
with rhabdomyosarcoma that represent mainly the pre-
pubertal age group, referral rates increased from 20 % in
the 3 years before the program was launched to 33 % (1/
5 patients and 2/6 patients respectively). Increase in referral
rates was documented in other cancer types (brain tumors,
lymphoma and high risk leukemia patients who were can-
didates for BMT). In 2009–2011 most of the patients that
were referred to FP were candidates for induction chemo-
therapy for BMT or high dose alkylating agents, mostly
pre-treated patients. Since one of the main rationales of the
program was to increase the awareness of the medical team
to early referral, the population of chemotherapy-naïve pa-
tients represents the major challenge.
Following the initiation of the program, younger pa-
tients are being referred after 2012 (6 patients below the
age of 10 years and 5 patients below the age of 5 years)
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as compared to the previous period before 2012 (t-test,
p < 0.05). Data regarding reproductive outcomes (ovarian
function, menstruation, future pregnancies) and onco-
logic outcomes (survival, recurrence etc.) is ongoing pro-
spectively collected.
Discussion
In an era of improving treatment protocols and subse-
quent increased survival of pediatric cancer patients,
where 5-year survival reaches 80 % [1, 2], fertility preser-
vation has become a pivotal survivorship issue. For
younger prepubertal female patients, ovarian tissue cryo-
preservation carries promise for future use in experi-
mental protocols, such as ovarian transplantation after
which live births had occurred, though only while the
tissue had been retrieved from adult patients [3]. In vitro
follicle maturation has been intensively studied and car-

































Fig. 3 Characteristics of referred patients (a) Patient distribution according to cancer type (b) Patient distribution according to therapeutic
protocol. Abbreviations: HL – Hodgkin’s lymphoma; AML – acute myeloid leukemia; ALL – acute lymphocytic leukemia; STS – soft tissue sarcoma;














Planned protocol No. of patients FP option
BMT 19 Ovarian cryopreservation
TBI/Craniospinal XRT 10 Ovarian cryopreservation










Fig. 4 Reproductive outcomes (a) Small antral follicles - distribution according to prior chemotherapy exposure (naïve, recent (<1 year), prior
chemotherapy (in case of cancer recurrence; >1y)). b In Vitro matured (frozen) oocytes; distribution according to prior chemotherapy exposure
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risk of disease recrudescence [22–24], especially for sur-
vivors of hematologic malignancies.
Former studies have evaluated the adherence of care
providers to ASCO recommendation of thorough dis-
cussion of fertility and referral to fertility preservation
[3]. Studies which assessed the patients’ notion on the
issue revealed that most of the adolescent patients as
well as parents of pediatric patients felt unsatisfied with
the degree of discussion and the very limited informa-
tion received, and the majority stated that they wished
to have a deeper discussion to resolve many unclear
questions and thoughts [25–27]. It has been formerly
established that other than actual preservation of fertility
for the future, the discussion and referral to FP helps the
patients to cope better with their condition and treat-
ment. Studies performed in adolescent males who were
referred to sperm banking demonstrated that sperm
banking was considered by the patients as a strong posi-
tive factor in coping emotionally with cancer [27, 28]. A
study of testicular preservation in prepubertal boys, re-
vealed that families are willing to undergo an experimen-
tal protocol even when there were no guarantees that
the science will exist in the future to allow their sons to
use this banked tissue to achieve pregnancy [29]. For
many parents and adolescents, the discussion of future
fertility is acknowledged as a discussion on the “day
after” and carries hope [29, 30]. From the medical facet,
provider perceptions were appraised in several studies
and revealed that although most oncologists recognized
the significance of discussing fertility with the patients,
in routine practice, less than half of the pediatric oncolo-
gists referred the patients to FP [31–33]. In an analysis
of the factors that contributed most to the lack of refer-
ral to FP, availability of fertility specialist and time con-
straints, were identified as the most common [31].
Former reports have implied that following develop-
ment of a designated and standardized process of offer-
ing FP to adolescents and young adults, there has been a
substantial increase in the proportion of patients that
were referred for FP [29, 34–36].
Our comprehensive multidisciplinary program was de-
veloped to pursue the complex issues associated with
fertility and cancer. We aimed to encompass both fertil-
ity preservation form the clinical aspect but also to em-
ploy this setting as a platform for translational research
on gonadotoxicity. The program was designed to provide
care for both male patients (for sperm banking and re-
cently a newly approved protocol of testicular biopsy
cryopreservation) and female patients (oocyte and ovar-
ian cryopreservation). From the clinical perspective, our
concept lied on the perceptions and needs observed in
our patient population on upon the literature. We
intended to raise the awareness of the caregivers to the
issue of fertility, facilitate the process of referral, and
serve as an approachable service for the patient. Once
notified by the treating oncologist, an appointment
would be scheduled within a short time and the algo-
rithm of referral would be operated. We refined the al-
gorithm of treatment based upon perceptions and
feedback from the patients, parents and the pediatric on-
cologists. We had found that an initial discussion per-
formed in the clinic by a trained oncologist contributed
to “priming” of the parents, who were then referred for a
broader discussion with the reproductive specialist and
a specialized psychologist of the reproductive endocrin-
ology service. Following the algorithm, the parents and
adolescents felt less stressful and less concerned of how
the FP procedure may affect their cancer (that was mostly
evident with adolescent pubertal patients that were under-


















Change in Referral Rate
2009-2011
2012-2014
Fig. 5 shifting paradigms – referral rate of chemo-naïve patients before and after initiation of a designated program. Bone tumors (Ewing sarcoma
and osteosarcoma), RMS - Rhabdomyosarcoma
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The multidisciplinary paradigm entails a better collabor-
ation between all disciplines – availability of personnel to
carry the appointments, flexibility of operation schedule
by skilled surgeons, and most importantly appropriate la-
boratory resources. By meticulous handling of the ovarian
tissue, we managed to aspirate immature germinal vesicle
oocytes that had already commenced maturation process
and to complete the maturation in vitro. By that, the
pediatric patient gained additional source of FP and had
not only stored ovarian tissue but rather mature oocytes.
The multidisciplinary infrastructure enables us to expand
our program also to testicular preservation in prepubertal
boys, a process which has been implemented very re-
cently. Our multidisciplinary program has led to a signifi-
cant increase in referrals of pediatric patients. With the
advent of oocyte cryopreservation as a standard option of
FP, the program facilitated this clinical application
reflected by higher referral rates of pubertal patients (that
up until recently were referred for embryo cryopreserva-
tion with sperm donation, an option that is considered
highly problematic for young adolescents). From the re-
search perspective, every patient that is referred to the
clinic is enrolled into an IRB-approved prospective longi-
tudinal study of gonadotoxicity related outcomes in young
patients who are treated with various anti-cancer therap-
ies. Gonadotoxic outcomes are serially measured even if
eventually the patient does not undergo actual fertility
preservation. Since there are very few prospective studies
assessing gonadal function and fertility in survivors of
childhood cancer, a longitudinal evaluation is imperative,
particularly with all newer regimens which their gonadal
effect remains to be elucidated. We also developed a par-
allel preclinical setting to study mechanisms of gonado-
toxicity of anti-cancer treatments in a mouse model.
Clinical dilemmas and questions are being translated into
studying the effect in the animal setting, while themes and
outcomes from the preclinical setting are being imple-
mented into observational studies in the patient cohort
(i.e. biomarkers for gonadal toxicity).
Due to the uncertainty over the risk of gonadotoxicity
and infertility associated with different treatment protocols
in children and young adults, it is mandatory to create a
“risk assessment” model to guide the decision on referral
to FP. The indication for FP in adolescents has become
broader since FP options have become standard (sperm
banking or oocyte cryopreservation) and not experimental.
Our strategy is to discuss these options with all patients
that are candidates for chemotherapy, not only highly
gonadotoxic (i.e. ABVD protocol). For the prepubertal
girls, risk assessment is performed by the treating oncolo-
gist. High risk patients are referred for FP, while intermedi-
ate risk are usually referred for discussion, and the actual
decision on FP would be made by the joined professional
team and the parents. Our results indicate that in
chemotherapy-naïve patients the yield of isolating imma-
ture oocytes from the retrieved ovary and the success rate
of IVM is significantly higher than in previously treated pa-
tients (even with less gonadotoxic regimens as anthracy-
clines). We therefore suggest a “risk assessment” process
before starting any treatment. If the chances of protocol
conversion into a high gonadotoxic regimen are high, the
case should be discussed in a multidisciplinary setting to
weigh whether the patient should be referred in advance
for FP to enhance the yield of fertility preservation.
Conclusion
With the advances of cancer treatments and the subse-
quent rise in survival, fertility has emerged as a highly
significant quality-of-life issue for young cancer patients.
Despite pediatric oncologists’ motivation to preserve fer-
tility in pediatric cancer patients, barriers to referral for
FP still persist. Multidisciplinary programs that encom-
pass experts of all relevant fields, skilled laboratory re-
sources and a facilitated path that eases the process and
conveys it in the shortest time, appear to maximize the
yield. We have observed a considerable higher referral
rates compared with the previous experience before the
launch of the program and higher satisfaction rate
among the patients and their parents that consider the
program as “an address” for fertility issues.
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